Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Hormone therapy alone isn't best treatment for receptor-positive cancer
December 28th, 2004
Many postmenopausal women with hormone-dependent breast cancer (i.e., cancer that requires estrogen and/or progesterone to grow) may be undertreated if they do not receive chemotherapy in addition to hormonal therapy after surgery. Kathy S. Albain of the Loyola University Health System, presented the results of a 10-year follow-up of The Breast Cancer Intergroup of North America Trial 0100 at the December 8, 2004, late-breaking session of the San Antonio Breast Cancer Symposium annual meeting. "The research shows that, in many cases, tamoxifen or other hormonal therapy alone is not optimal," said principal investigator and first author Albain,...
Source: Cancer Weekly (2004-12-28)
|
